+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Respiratory Syncytial Virus (RSV) Therapeutics: Global Strategic Business Report

  • PDF Icon

    Report

  • 194 Pages
  • September 2023
  • Region: Global
  • Global Industry Analysts, Inc
  • ID: 5310780

Quick Summary:

The global Respiratory Syncytial Virus (RSV) Therapeutics market is on a dramatic trajectory, projected to catapult from a valuation of $1 Billion in 2022 to an astonishing $7.8 Billion by 2030. Align your business with this rapid acceleration by acknowledging the detailed insights provided by our thoroughly researched RSV Therapeutics market report.

This report offers a comprehensive analysis of important segments such as Prophylaxis, showing an impressive CAGR prediction of 28.5%, and Treatment, reflecting a surge to a revised 34.8% CAGR in the upcoming eight years. Featuring notable geographies, it provides an unparalleled understanding of emerging markets like China, set to trail a 28% CAGR over the analysis period. The stewardship and strategic planning facilitated by this report are indispensable in navigating this dynamic sector. With in-depth competitive analysis featuring 41 industry leaders, the report serves as a navigational compass in this rapidly evolving market.

Global Respiratory Syncytial Virus (RSV) Therapeutics Market to Reach $7.8 Billion by 2030

The global market for Respiratory Syncytial Virus (RSV) Therapeutics estimated at US$1 Billion in the year 2022, is projected to reach a revised size of US$7.8 Billion by 2030, growing at a CAGR of 29.2% over the analysis period 2022-2030. Prophylaxis, one of the segments analyzed in the report, is projected to record 28.5% CAGR and reach US$6.8 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Treatment segment is readjusted to a revised 34.8% CAGR for the next 8-year period.

The U.S. Market is Estimated at $304 Million, While China is Forecast to Grow at 28% CAGR

The Respiratory Syncytial Virus (RSV) Therapeutics market in the U.S. is estimated at US$304 Million in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$1.3 Billion by the year 2030 trailing a CAGR of 28% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 26.3% and 25% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 20.4% CAGR.

Select Competitors (Total 41 Featured) -

  • AbbVie, Inc.
  • AstraZeneca PLC
  • Bausch Health Companies Inc.
  • F. Hoffmann-La Roche AG
  • Gilead Sciences, Inc.
  • GlaxoSmithKline PLC
  • Merck & Co., Inc.
  • ReViral Ltd.
  • Teva Pharmaceutical Industries Ltd.

What's New?

  • Special coverage on Russia-Ukraine war; global inflation; easing of zero-Covid policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.
  • Global competitiveness and key competitor percentage market shares
  • Market presence across multiple geographies - Strong/Active/Niche/Trivial
  • Online interactive peer-to-peer collaborative bespoke updates
  • Access to digital archives and the publisher's Research Platform
  • Complimentary updates for one year

Frequently Asked Questions about the Global Market for Respiratory Syncytial Virus (RSV) Therapeutics

What is the estimated value of the Global Market for Respiratory Syncytial Virus (RSV) Therapeutics?

The Global Market for Respiratory Syncytial Virus (RSV) Therapeutics was estimated to be valued at $1 Billion in 2022.

What is the growth rate of the Global Market for Respiratory Syncytial Virus (RSV) Therapeutics?

The growth rate of the Global Market for Respiratory Syncytial Virus (RSV) Therapeutics is 29.3%, with an estimated value of $7.8 Billion by 2030.

What is the forecasted size of the Global Market for Respiratory Syncytial Virus (RSV) Therapeutics?

The Global Market for Respiratory Syncytial Virus (RSV) Therapeutics is estimated to be worth $7.8 Billion by 2030.

Who are the key companies in the Global Market for Respiratory Syncytial Virus (RSV) Therapeutics?

Key companies in the Global Market for Respiratory Syncytial Virus (RSV) Therapeutics include AbbVie, Inc., AstraZeneca PLC, Bausch Health Companies Inc., F. Hoffmann, La Roche AG, Gilead Sciences, Inc., GlaxoSmithKline PLC, Merck & Co., Inc., ReViral Ltd. and Teva Pharmaceutical Industries Ltd..

Table of Contents

I. METHODOLOGYII. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Respiratory Syncytial Virus (RSV) Therapeutics - Global Key Competitors Percentage Market Share in 2022 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
  • Impact of Covid-19 and a Looming Global Recession
2. FOCUS ON SELECT PLAYERS3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
  • Table 1: World Respiratory Syncytial Virus (RSV) Therapeutics Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
  • Table 2: World Recent Past, Current & Future Analysis for Respiratory Syncytial Virus (RSV) Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
  • Table 3: World Historic Review for Respiratory Syncytial Virus (RSV) Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
  • Table 4: World 16-Year Perspective for Respiratory Syncytial Virus (RSV) Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2023 & 2030
  • Table 5: World Recent Past, Current & Future Analysis for Prophylaxis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
  • Table 6: World Historic Review for Prophylaxis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
  • Table 7: World 16-Year Perspective for Prophylaxis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
  • Table 8: World Recent Past, Current & Future Analysis for Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
  • Table 9: World Historic Review for Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
  • Table 10: World 16-Year Perspective for Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
  • Table 11: World Recent Past, Current & Future Analysis for Hospital Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
  • Table 12: World Historic Review for Hospital Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
  • Table 13: World 16-Year Perspective for Hospital Pharmacy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
  • Table 14: World Recent Past, Current & Future Analysis for Retail Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
  • Table 15: World Historic Review for Retail Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
  • Table 16: World 16-Year Perspective for Retail Pharmacy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
  • Table 17: World Recent Past, Current & Future Analysis for Online by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
  • Table 18: World Historic Review for Online by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
  • Table 19: World 16-Year Perspective for Online by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
III. MARKET ANALYSIS
  • UNITED STATES
  • Respiratory Syncytial Virus (RSV) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2023 (E)
  • Table 20: USA Recent Past, Current & Future Analysis for Respiratory Syncytial Virus (RSV) Therapeutics by Drug Class - Prophylaxis and Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • Table 21: USA Historic Review for Respiratory Syncytial Virus (RSV) Therapeutics by Drug Class - Prophylaxis and Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
  • Table 22: USA 16-Year Perspective for Respiratory Syncytial Virus (RSV) Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Prophylaxis and Treatment for the Years 2014, 2023 & 2030
  • Table 23: USA Recent Past, Current & Future Analysis for Respiratory Syncytial Virus (RSV) Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • Table 24: USA Historic Review for Respiratory Syncytial Virus (RSV) Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
  • Table 25: USA 16-Year Perspective for Respiratory Syncytial Virus (RSV) Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online for the Years 2014, 2023 & 2030
  • CANADA
  • Table 26: Canada Recent Past, Current & Future Analysis for Respiratory Syncytial Virus (RSV) Therapeutics by Drug Class - Prophylaxis and Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • Table 27: Canada Historic Review for Respiratory Syncytial Virus (RSV) Therapeutics by Drug Class - Prophylaxis and Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
  • Table 28: Canada 16-Year Perspective for Respiratory Syncytial Virus (RSV) Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Prophylaxis and Treatment for the Years 2014, 2023 & 2030
  • Table 29: Canada Recent Past, Current & Future Analysis for Respiratory Syncytial Virus (RSV) Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • Table 30: Canada Historic Review for Respiratory Syncytial Virus (RSV) Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
  • Table 31: Canada 16-Year Perspective for Respiratory Syncytial Virus (RSV) Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online for the Years 2014, 2023 & 2030
  • JAPAN
  • Respiratory Syncytial Virus (RSV) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2023 (E)
  • Table 32: Japan Recent Past, Current & Future Analysis for Respiratory Syncytial Virus (RSV) Therapeutics by Drug Class - Prophylaxis and Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • Table 33: Japan Historic Review for Respiratory Syncytial Virus (RSV) Therapeutics by Drug Class - Prophylaxis and Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
  • Table 34: Japan 16-Year Perspective for Respiratory Syncytial Virus (RSV) Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Prophylaxis and Treatment for the Years 2014, 2023 & 2030
  • Table 35: Japan Recent Past, Current & Future Analysis for Respiratory Syncytial Virus (RSV) Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • Table 36: Japan Historic Review for Respiratory Syncytial Virus (RSV) Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
  • Table 37: Japan 16-Year Perspective for Respiratory Syncytial Virus (RSV) Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online for the Years 2014, 2023 & 2030
  • CHINA
  • Respiratory Syncytial Virus (RSV) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2023 (E)
  • Table 38: China Recent Past, Current & Future Analysis for Respiratory Syncytial Virus (RSV) Therapeutics by Drug Class - Prophylaxis and Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • Table 39: China Historic Review for Respiratory Syncytial Virus (RSV) Therapeutics by Drug Class - Prophylaxis and Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
  • Table 40: China 16-Year Perspective for Respiratory Syncytial Virus (RSV) Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Prophylaxis and Treatment for the Years 2014, 2023 & 2030
  • Table 41: China Recent Past, Current & Future Analysis for Respiratory Syncytial Virus (RSV) Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • Table 42: China Historic Review for Respiratory Syncytial Virus (RSV) Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
  • Table 43: China 16-Year Perspective for Respiratory Syncytial Virus (RSV) Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online for the Years 2014, 2023 & 2030
  • EUROPE
  • Respiratory Syncytial Virus (RSV) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2023 (E)
  • Table 44: Europe Recent Past, Current & Future Analysis for Respiratory Syncytial Virus (RSV) Therapeutics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
  • Table 45: Europe Historic Review for Respiratory Syncytial Virus (RSV) Therapeutics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
  • Table 46: Europe 16-Year Perspective for Respiratory Syncytial Virus (RSV) Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2023 & 2030
  • Table 47: Europe Recent Past, Current & Future Analysis for Respiratory Syncytial Virus (RSV) Therapeutics by Drug Class - Prophylaxis and Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • Table 48: Europe Historic Review for Respiratory Syncytial Virus (RSV) Therapeutics by Drug Class - Prophylaxis and Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
  • Table 49: Europe 16-Year Perspective for Respiratory Syncytial Virus (RSV) Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Prophylaxis and Treatment for the Years 2014, 2023 & 2030
  • Table 50: Europe Recent Past, Current & Future Analysis for Respiratory Syncytial Virus (RSV) Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • Table 51: Europe Historic Review for Respiratory Syncytial Virus (RSV) Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
  • Table 52: Europe 16-Year Perspective for Respiratory Syncytial Virus (RSV) Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online for the Years 2014, 2023 & 2030
  • FRANCE
  • Respiratory Syncytial Virus (RSV) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2023 (E)
  • Table 53: France Recent Past, Current & Future Analysis for Respiratory Syncytial Virus (RSV) Therapeutics by Drug Class - Prophylaxis and Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • Table 54: France Historic Review for Respiratory Syncytial Virus (RSV) Therapeutics by Drug Class - Prophylaxis and Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
  • Table 55: France 16-Year Perspective for Respiratory Syncytial Virus (RSV) Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Prophylaxis and Treatment for the Years 2014, 2023 & 2030
  • Table 56: France Recent Past, Current & Future Analysis for Respiratory Syncytial Virus (RSV) Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • Table 57: France Historic Review for Respiratory Syncytial Virus (RSV) Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
  • Table 58: France 16-Year Perspective for Respiratory Syncytial Virus (RSV) Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online for the Years 2014, 2023 & 2030
  • GERMANY
  • Respiratory Syncytial Virus (RSV) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2023 (E)
  • Table 59: Germany Recent Past, Current & Future Analysis for Respiratory Syncytial Virus (RSV) Therapeutics by Drug Class - Prophylaxis and Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • Table 60: Germany Historic Review for Respiratory Syncytial Virus (RSV) Therapeutics by Drug Class - Prophylaxis and Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
  • Table 61: Germany 16-Year Perspective for Respiratory Syncytial Virus (RSV) Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Prophylaxis and Treatment for the Years 2014, 2023 & 2030
  • Table 62: Germany Recent Past, Current & Future Analysis for Respiratory Syncytial Virus (RSV) Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • Table 63: Germany Historic Review for Respiratory Syncytial Virus (RSV) Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
  • Table 64: Germany 16-Year Perspective for Respiratory Syncytial Virus (RSV) Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online for the Years 2014, 2023 & 2030
  • ITALY
  • Table 65: Italy Recent Past, Current & Future Analysis for Respiratory Syncytial Virus (RSV) Therapeutics by Drug Class - Prophylaxis and Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • Table 66: Italy Historic Review for Respiratory Syncytial Virus (RSV) Therapeutics by Drug Class - Prophylaxis and Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
  • Table 67: Italy 16-Year Perspective for Respiratory Syncytial Virus (RSV) Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Prophylaxis and Treatment for the Years 2014, 2023 & 2030
  • Table 68: Italy Recent Past, Current & Future Analysis for Respiratory Syncytial Virus (RSV) Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • Table 69: Italy Historic Review for Respiratory Syncytial Virus (RSV) Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
  • Table 70: Italy 16-Year Perspective for Respiratory Syncytial Virus (RSV) Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online for the Years 2014, 2023 & 2030
  • UNITED KINGDOM
  • Respiratory Syncytial Virus (RSV) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2023 (E)
  • Table 71: UK Recent Past, Current & Future Analysis for Respiratory Syncytial Virus (RSV) Therapeutics by Drug Class - Prophylaxis and Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • Table 72: UK Historic Review for Respiratory Syncytial Virus (RSV) Therapeutics by Drug Class - Prophylaxis and Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
  • Table 73: UK 16-Year Perspective for Respiratory Syncytial Virus (RSV) Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Prophylaxis and Treatment for the Years 2014, 2023 & 2030
  • Table 74: UK Recent Past, Current & Future Analysis for Respiratory Syncytial Virus (RSV) Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • Table 75: UK Historic Review for Respiratory Syncytial Virus (RSV) Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
  • Table 76: UK 16-Year Perspective for Respiratory Syncytial Virus (RSV) Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online for the Years 2014, 2023 & 2030
  • REST OF EUROPE
  • Table 77: Rest of Europe Recent Past, Current & Future Analysis for Respiratory Syncytial Virus (RSV) Therapeutics by Drug Class - Prophylaxis and Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • Table 78: Rest of Europe Historic Review for Respiratory Syncytial Virus (RSV) Therapeutics by Drug Class - Prophylaxis and Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
  • Table 79: Rest of Europe 16-Year Perspective for Respiratory Syncytial Virus (RSV) Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Prophylaxis and Treatment for the Years 2014, 2023 & 2030
  • Table 80: Rest of Europe Recent Past, Current & Future Analysis for Respiratory Syncytial Virus (RSV) Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • Table 81: Rest of Europe Historic Review for Respiratory Syncytial Virus (RSV) Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
  • Table 82: Rest of Europe 16-Year Perspective for Respiratory Syncytial Virus (RSV) Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online for the Years 2014, 2023 & 2030
  • ASIA-PACIFIC
  • Respiratory Syncytial Virus (RSV) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2023 (E)
  • Table 83: Asia-Pacific Recent Past, Current & Future Analysis for Respiratory Syncytial Virus (RSV) Therapeutics by Drug Class - Prophylaxis and Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • Table 84: Asia-Pacific Historic Review for Respiratory Syncytial Virus (RSV) Therapeutics by Drug Class - Prophylaxis and Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
  • Table 85: Asia-Pacific 16-Year Perspective for Respiratory Syncytial Virus (RSV) Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Prophylaxis and Treatment for the Years 2014, 2023 & 2030
  • Table 86: Asia-Pacific Recent Past, Current & Future Analysis for Respiratory Syncytial Virus (RSV) Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • Table 87: Asia-Pacific Historic Review for Respiratory Syncytial Virus (RSV) Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
  • Table 88: Asia-Pacific 16-Year Perspective for Respiratory Syncytial Virus (RSV) Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online for the Years 2014, 2023 & 2030
  • REST OF WORLD
  • Table 89: Rest of World Recent Past, Current & Future Analysis for Respiratory Syncytial Virus (RSV) Therapeutics by Drug Class - Prophylaxis and Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • Table 90: Rest of World Historic Review for Respiratory Syncytial Virus (RSV) Therapeutics by Drug Class - Prophylaxis and Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
  • Table 91: Rest of World 16-Year Perspective for Respiratory Syncytial Virus (RSV) Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Prophylaxis and Treatment for the Years 2014, 2023 & 2030
  • Table 92: Rest of World Recent Past, Current & Future Analysis for Respiratory Syncytial Virus (RSV) Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • Table 93: Rest of World Historic Review for Respiratory Syncytial Virus (RSV) Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
  • Table 94: Rest of World 16-Year Perspective for Respiratory Syncytial Virus (RSV) Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online for the Years 2014, 2023 & 2030
IV. COMPETITION

Companies Mentioned

A selection of companies mentioned in this report includes:

  • AbbVie, Inc.
  • AstraZeneca PLC
  • Bausch Health Companies Inc.
  • F. Hoffmann-La Roche AG
  • Gilead Sciences, Inc.
  • GlaxoSmithKline PLC
  • Merck & Co., Inc.
  • ReViral Ltd.
  • Teva Pharmaceutical Industries Ltd.